Horizon at a Glance

- Focused on rare patient populations
- Personally invested in our patients wherever they are in their journey
- More than 1,200 employees
- Our medicines treat rare and rheumatic conditions
- Corporate headquarters in Dublin, Ireland, with U.S. operations in Lake Forest, Illinois
We are Bringing Forward Medicines That Address Unmet Needs in Both Rare and Rheumatic Disease

**RARE DISEASE**
- Urea Cycle Disorder, Cystinosis, Chronic Granulomatous Disease, Severe Malignant Osteopetrosis, Thyroid Eye Disease

**RHEUMATIC DISEASE**
- Osteoarthritis, Rheumatoid Arthritis, Polymyalgia Rheumatica, Ankylosing Spondylitis, Uncontrolled Gout

- 7 Out of 11 medicines for the treatment of RARE DISEASES
- 3 New clinical research programs for DEVELOPMENT STAGE MEDICINES
- 6 Research programs EXPLORE THE FURTHER USE OF OUR CURRENT MEDICINES
# Building a Robust Rare Disease Pipeline

<table>
<thead>
<tr>
<th>MEDICINE / PROGRAM</th>
<th>DESCRIPTION</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>PHASE 3b/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRYSTEXXA Immunomodulation</td>
<td>• MIRROR randomized controlled trial (RCT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRYSTEXXA Nephrology</td>
<td>• PROTECT open-label trial in kidney transplant patients with uncontrolled gout</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRYSTEXXA Shorter-Infusion Duration(^{(1)})</td>
<td>• Open-label trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEPEZZA Chronic (Inactive) Thyroid Eye Disease(^{(1)})</td>
<td>• Phase 4 trial in chronic TED patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEPEZZA Thyroid Eye Disease</td>
<td>• OPTIC-X: Phase 3 extension trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZN-825 Diffuse Cutaneous Systemic Sclerosis(^{(1)})</td>
<td>• Phase 2b pivotal trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEPEZZA Diffuse Cutaneous Systemic Sclerosis(^{(1)})</td>
<td>• Exploratory trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEPEZZA Subcutaneous Administration(^{(1)})</td>
<td>• Pharmacokinetic trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZN-003 Next-Gen Uncontrolled Gout</td>
<td>• Exploration of optimized uricase and optimized PEGylation for uncontrolled gout</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZN-007 Next-Gen Uncontrolled Gout(^{(2)})</td>
<td>• Exploration of optimized uricase and PASylation for uncontrolled gout</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HemoShear Gout Discovery Collaboration</td>
<td>• Exploration of novel approaches to treating gout</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

New trial announced in 2020.

\(^{(1)}\) Trial not yet initiated.

\(^{(2)}\) Being developed under a collaboration agreement with XL Protein GmbH.

MIRROR: Trial evaluating the use of KRYSTEXXA in combination with methotrexate to increase the response rate.

PROTECT: Trial evaluating the effect of KRYSTEXXA on serum uric acid levels in kidney transplant patients with uncontrolled gout.

OPTIC-X: Open-label extension trial of the Phase 3 trial evaluating TEPEZZA for the treatment of thyroid eye disease.

YTD: Year to date.
Heart of Horizon: Commitment Beyond Our Medicines
We Participate, Listen and Learn with Our Disease Communities

+60
Patient advocacy group partnerships globally

+1,000
Employees take part in hundreds of advocacy events around the world
We Create Change in Our Community: Annual Impact

- **Non-profits supported**: +60
- **Provided in patient support**: $1.5b
- **Meals packed for Feeding Children Everywhere**: +152k
- **Pillars of giving in healthcare, STEAM, environmental sustainability and innovation**: 4
- **In support of our communities**: +$12m
- **Invested in Perspectives Math & Science Academy**: +$1m
- **Of the 17 United Nations Sustainable Development Goals supported**: 11
“Going above and beyond for patients is what we do every day. It is at the core of our company culture and reflects my own experience as a patient.”

Tim Walbert
Chairman, President and CEO
Thank you